Literature DB >> 10861476

Pre-malignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process.

V De Re1, S De Vita, A Marzotto, A Gloghini, B Pivetta, D Gasparotto, R Cannizzaro, A Carbone, M Boiocchi.   

Abstract

Type II mixed cryoglobulinemia (MC) is a systemic vasculitis characterized by the presence in the serum of a monoclonal cryoprecipitable IgM with rheumatoid factor (RF) activity. Hepatitis C virus (HCV) has been recognized as its major etiologic factor. Because MC frequently evolves into overt B-cell non-Hodgkin's lymphoma (NHL), chronic HCV infection is hypothesized to lead to both benign and malignant lymphoproliferative disease. In this study, we investigated mutations in the V(H) and V(K) genes of the B-cell clone originating the overt B-cell lymphoma in a subject with MC. Mutational patterns were analyzed longitudinally in two bone marrow biopsies obtained at the stage of MC, as well as in multiple involved tissues (bone marrow, liver, and peripheral blood cells) at the stage of overt NHL. Hybridization of variable-diversity-joining (VDJ) PCR products with a probe specific for the neoplastic clone indicated that the lymphoma originated from one of the clones over-stimulated during MC. This clone producing an IgM highly homologous to a protein with RF specificity may explain the MC syndrome in the patient. Moreover, the presence of an IgH ongoing mutation process and the expression of an Ig antigen receptor significantly homologous to an anti-HCV protein support the hypothesis that the MC syndrome and the subsequent evolution to NHL are antigen-driven lymphoproliferative processes possibly sustained by HCV. Furthermore, the marked reduction in intra-clonal diversity in the last bone marrow biopsy obtained at the stage of overt NHL points out a minor dependence of the cells on the antigen-driven mechanism, although an intrinsic propensity of the neoplastic cell to undergo replacement mutations cannot be excluded. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861476     DOI: 10.1002/1097-0215(20000715)87:2<211::aid-ijc9>3.0.co;2-8

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

Review 1.  Hepatitis viruses and non-Hodgkin's lymphoma: A review.

Authors:  Sibnarayan Datta; Soumya Chatterjee; Rudragoud S Policegoudra; Hemant K Gogoi; Lokendra Singh
Journal:  World J Virol       Date:  2012-12-12

Review 2.  Cryoglobulins.

Authors:  C Ferri; A L Zignego; S A Pileri
Journal:  J Clin Pathol       Date:  2002-01       Impact factor: 3.411

Review 3.  Role of hepatitis C virus in B cell lymphoproliferations.

Authors:  Felicia Tucci; Ralf Küppers
Journal:  Virol Sin       Date:  2014-02       Impact factor: 4.327

Review 4.  Non-Hodgkin lymphoma and hepatitis C: where we are and what next?

Authors:  Mihály Sulyok; Mihály Makara; Eszter Újhelyi; István Vályi-Nagy
Journal:  Pathol Oncol Res       Date:  2014-10-02       Impact factor: 3.201

Review 5.  Primary, post-primary and non-specific immunoglobulin M responses in HCV infection.

Authors:  Lynn B Dustin; Edgar D Charles
Journal:  Antivir Ther       Date:  2012-12-07

6.  Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Marialina Tornesello; Maria Napolitano; Debora Martorelli; Giuseppe Castello; Gerardo Beneduce; Amalia De Renzo; Oreste Perrella; Luca Romagnoli; Vitor Sousa; Valli De Re; Riccardo Dolcetti; Franco M Buonaguro
Journal:  J Transl Med       Date:  2010-02-19       Impact factor: 5.531

7.  Characterization of the light chain-restricted clonal B cells in peripheral blood of HCV-positive patients.

Authors:  Korenori Ohtsubo; Michio Sata; Takumi Kawaguchi; Satoshi Morishige; Yuka Takata; Eijiro Oku; Rie Imamura; Ritsuko Seki; Michitoshi Hashiguchi; Koichi Osaki; Kazuaki Yakushiji; Taisuke Kanaji; Kohji Yoshimoto; Takato Ueno; Takashi Okamura
Journal:  Int J Hematol       Date:  2009-04-08       Impact factor: 2.490

Review 8.  Innate and Adaptive Immune Responses in Chronic HCV Infection.

Authors:  Lynn B Dustin
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

Review 9.  Immune control and failure in HCV infection--tipping the balance.

Authors:  Lynn B Dustin; Siobhán B Cashman; Stephen M Laidlaw
Journal:  J Leukoc Biol       Date:  2014-07-11       Impact factor: 4.962

10.  Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia.

Authors:  Edgar D Charles; Rashidah M Green; Svetlana Marukian; Andrew H Talal; Gerond V Lake-Bakaar; Ira M Jacobson; Charles M Rice; Lynn B Dustin
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.